Article
Dermatology
Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. R. Feldman
Summary: This study described the persistence and remission rates of patients with psoriasis initiated on current biologics. The results showed that patients using guselkumab had longer persistence and higher remission rates compared to other biologics.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Emanuele Trovato, Corinne Orsini, Filomena Russo, Giulio Cortonesi, Pietro Rubegni
Summary: Erythodermic psoriasis is a rare subset of psoriasis considered a dermatologic emergency, with limited clinical evidence and unknown pathogenesis. In addition to conventional therapies, studies suggest that biologics may be a new treatment option.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Zenas Z. N. Yiu, Gabrielle Becher, Brian Kirby, Philip Laws, Nick J. Reynolds, Catherine H. Smith, Richard B. Warren, Christopher E. M. Griffiths
Summary: The results of this cohort study suggest that guselkumab had the highest drug survival among the included biologics for treating psoriasis in terms of effectiveness, and guselkumab had the highest drug survival for safety compared with other biologics except ustekinumab.
Article
Dermatology
Luca Mastorino, Paolo Dapavo, Sara Susca, Caterina Cariti, Niccolo Siliquini, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Pietro Quaglino, Simone Ribero
Summary: IL-23 inhibitors showed the best performance in drug survival for patients with psoriasis. IL-17 inhibitors were more effective in the short-term, but anti-IL-23 showed better long-term effectiveness. Male patients and those treated with risankizumab and guselkumab had a lower probability of drug interruption.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Article
Dermatology
L. S. van der Schoot, J. J. Janssen, M. T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D. N. H. Enomoto, R. Hovingh, R. A. Tupker, M. M. B. Seyger, L. M. Verhoef, J. M. P. A. van den Reek, E. M. G. J. de Jong
Summary: Implementation of protocolized biologic dose reduction can increase patient uptake of treatment, with additional staff support, extra consultation time, education for healthcare providers and patients, and effective tools such as a feasible protocol leading to more patients on biologic dose reduction.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Gayle van der Kraaij, Celine Busard, Juul van den Reek, Stef Menting, Annelie Musters, Barbara Hutten, Menno de Rie, Wouter Ouwerkerk, Sun-Jine Van Bezooijen, Errol Prens, Theo Rispens, Annick de Vries, Elke de Jong, Wim de Kort, Jo Lambert, Martijn van Doorn, Phyllis Spuls
Summary: This study evaluated the efficacy, safety, and pharmacokinetic profile of adalimumab combined with methotrexate in the treatment of chronic plaque psoriasis. The results showed that combination therapy resulted in fewer patients showing antidrug antibodies and a trend towards improved treatment response.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Seung-Won Jung, Sung Ha Lim, Jae Joon Jeon, Yeon-Woo Heo, Mi Soo Choi, Seung-Phil Hong
Summary: This study compared the efficacy, safety, and drug survival of three commonly used psoriasis biologics and identified factors affecting drug survival. Guselkumab showed superior long-term response and complete remission compared to other biologics, while ustekinumab had lower efficacy. All three biologics had similar safety profiles, but had different side effects.
Article
Dermatology
Jian Gong, Weiwei Wu, Liguo Qiu, Xi Wang, Jianwei Bao, Jinjing Wang, Lifang Cheng, Zhiyuan Fu, Fengming Hu
Summary: This is a case report of a patient with both psoriasis and HIV infection. The study found that using anti-IL-17 monoclonal antibodies as treatment had good effects on both psoriasis and arthritis symptoms.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2022)
Article
Dermatology
Benjamin Lockshin, Ryan W. Harrison, Robert R. McLean, Margaux M. Crabtree, Bruce W. Konicek, Baojin Zhu, William N. Malatestinic, Bilal Atiya, Mwangi J. Murage, Russel T. Burge
Summary: This study aims to compare the effectiveness of ixekizumab in psoriasis patients who previously failed secukinumab and other biologics. The results demonstrate that patients who switched to ixekizumab after discontinuing another biologic showed improvement in disease severity after six months. Patients who discontinued biologics other than secukinumab were more likely to respond to ixekizumab.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Selma Atalay, Lara S. van der Schoot, Laura Vandermaesen, Lieke J. van Vugt, Mascha Eilander, Juul M. P. A. van den Reek, Elke M. G. J. de Jong
Summary: The study found that a tightly controlled dose reduction strategy for adalimumab, etanercept, and ustekinumab in patients with psoriasis can safely decrease drug dosages and maintain the use of lower doses.
ACTA DERMATO-VENEREOLOGICA
(2021)
Article
Dermatology
James Krueger, Richard G. Langley, Simon Nigen, Torben Kasparek, Gabriele Di Comite, Christine-Elke Ortmann, Sandra Garcet, Frank Kolbinger, Kristian Reich
Summary: This study aimed to investigate the clinical and molecular effects of direct IL-17A (with secukinumab) versus selective IL-23 inhibition (with guselkumab) in patients with anti-IL-12/23-refractory psoriatic plaques. The results showed that secukinumab demonstrated a greater clinical and molecular effect on ustekinumab-refractory psoriatic plaques compared with guselkumab, supporting the hypothesis that IL-23-independent IL-17 mechanisms may be relevant to the persistent manifestations of psoriasis.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Yue Xiao, Hui Chen, Qin Zou, Yiyi Wang, Yuanxia Gu, Jinqiu Wang, Wei Yan, Wei Li
Summary: This study aimed to investigate the tuberculosis infection status conversion ratio among psoriasis patients treated with adalimumab and secukinumab in China. The results showed a relatively high rate of tuberculosis conversion among these patients after an average treatment duration of 17.13 months.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Cheng-Ying Chiang, Tsen-Fang Tsai
Summary: Guselkumab has shown promising results in the treatment of erythrodermic psoriasis, but its efficacy and drug survival in EP patients still need to be further studied. Our data provide real-world experience of guselkumab treatment in this rare group of patients, with PASI response at week 12 being a good predictor of patient response and drug survival.
DERMATOLOGY AND THERAPY
(2021)
Article
Dermatology
Lisa Schots, Rani Soenen, Brigitte Blanquart, Debby Thomas, Jo Lambert
Summary: This real-world study demonstrates that IL-17i are highly effective drugs for the treatment of psoriasis, with ixekizumab as the most effective biologic. Treatment modifications mainly occur in cases of inadequate response, primarily through switching medications and increasing doses, and least frequently in ixekizumab patients. Concentrations of the drug may rationalize clinical decision-making, but standardized algorithms are needed to validate its use.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Ying Li, Jia-Jing Lu, Xiao-Yuan Zhong, Ying-Yuan Yu, Ning Yu, Yu Wang, Xue-Mei Yi, Yang-Feng Ding, Yu-Ling Shi
Summary: This study compared the drug survival rates of different biologics used to treat psoriasis in real-world conditions. The results showed that guselkumab had superior drug survival, while ixekizumab and secukinumab had comparable outcomes and were significantly better than adalimumab in China.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2022)